Oxaliplatin and ototoxicity: is it really safe for hearing?

Oxaliplatin is an effective and widely used chemotherapeutic agent in the treatment of many solid tumors. The most common side effects are peripheral neuropathy, gastrointestinal toxicity, and neutropenia. There have been some case reports about ototoxicity with oxaliplatin, but no clinical trials. In this trial, we explored whether or not oxaliplatin has ototoxic effects. Materials and methods: A total of 18 patients, 14 with colorectal cancer and 4 with pancreatic cancer, were included in this study. Four patients (22%) were treated with a capecitabine and oxaliplatin (CapeOx) regimen, and 14 patients (78%) were treated with fluorouracil, leucovorin, and oxaliplatin (FOLFOX-6). Patients' pretreatment and posttreatment hearing levels were assessed with high-frequency audiometry and otoacoustic emission tests. Results: The median time between the first and the last oxaliplatin doses was 3.2 months (range: 2-7 months). There was no hearing loss in tests conducted for both ears of patients at frequencies of 500, 1000, 2000, 4000, 6000, 8000, 12,000, and 16,000 Hz. There was no difference between the pretreatment and posttreatment otoacoustic emission tests. Conclusion: Oxaliplatin is a reliable agent in terms of ototoxicity.

Oxaliplatin and ototoxicity: is it really safe for hearing?

Oxaliplatin is an effective and widely used chemotherapeutic agent in the treatment of many solid tumors. The most common side effects are peripheral neuropathy, gastrointestinal toxicity, and neutropenia. There have been some case reports about ototoxicity with oxaliplatin, but no clinical trials. In this trial, we explored whether or not oxaliplatin has ototoxic effects. Materials and methods: A total of 18 patients, 14 with colorectal cancer and 4 with pancreatic cancer, were included in this study. Four patients (22%) were treated with a capecitabine and oxaliplatin (CapeOx) regimen, and 14 patients (78%) were treated with fluorouracil, leucovorin, and oxaliplatin (FOLFOX-6). Patients' pretreatment and posttreatment hearing levels were assessed with high-frequency audiometry and otoacoustic emission tests. Results: The median time between the first and the last oxaliplatin doses was 3.2 months (range: 2-7 months). There was no hearing loss in tests conducted for both ears of patients at frequencies of 500, 1000, 2000, 4000, 6000, 8000, 12,000, and 16,000 Hz. There was no difference between the pretreatment and posttreatment otoacoustic emission tests. Conclusion: Oxaliplatin is a reliable agent in terms of ototoxicity.

Kaynakça

André T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan P, Bridgewater J et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343– 23

Kuebler JP, Wieand HS, O’Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN G et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198–2204.

André T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol 2009; 27: 3109–3116.

Extra JM, Espie M, Calvo F, Ferme C, Mignot L, Marty M. Phase I study of oxaliplatin in patients with advanced cancer. Cancer Chemother Pharmacol 1990; 25: 299–303.

Saif MW, Reardon J. Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 2005; 1: 249– 2

Moroso M, Blair R. A review of cis-platinum ototoxicity. J Otolaryngol 1983; 12: 356–359.

Seligman H, Podoshin L, Ben-David J, Fradis M, Goldsher M. Drug-induced tinnitus and other hearing disorders. Drug Saf 1996; 14: 198–212.

Reddel RR, Kefford RF, Grant JM, Coates AS, Fox RM, Tattersall MH. Ototoxicity in patients receiving cisplatin: importance of dose and method of drug administration. Cancer Treat Rep 1982; 66: 19–23.

Şanlı A, Aydın S, Sarısoy ZA, Paksoy M, Ayduran E, Çelebi Erdivanlı Ö. The protective effect of dexamethasone and lactate against cisplatin-induced ototoxicity. Turk J Med Sci 2011; 41: 467–474.

Dutta A, Venkatesh MD, Kashyap RC. Study of the effects of chemotherapy on auditory function. Indian J Otolaryngol Head Neck Surg 2005; 57: 226–228.

Kennedy IC, Fitzharris BM, Colls BM, Atkinson CH. Carboplatin is ototoxic. Cancer Chemother Pharmacol 1990; 26: 232–234.

Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9–23.

Montaguti M, Brandolini C, Ferri GG, Hatzopoulos S, Prete A, Pession A. Cisplatin and carboplatin-induced ototoxicity in children: clinical aspects and perspectives for prevention. Acta Otorhinolaryngol Ital 2002; 22: 14–18.

Arkenau HT, Arnold D, Cassidy J, Diaz-Rubio E, Douillard JY, Hochster H, Martoni A, Grothey A, Hinke A, Schmiegel W et al. Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trials. J Clin Oncol 2008; 26: 5910–5917.

Twelves C, Scheithauer W, McKendrick J, Seitz JF, Van Hazel G, Wong A, Díaz-Rubio E, Gilberg F, Cassidy J. Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy Ann Oncol 2012; 23: 1190–1197.

Hellberg V, Wallin I, Eriksson S, Hernlund E, Jerremalm E, Berndtsson M, Eksborg S, Arnér ES, Shoshan M, Ehrsson H et al. Cisplatin and oxaliplatin toxicity: importance of cochlear kinetics as a determinant for ototoxicity. J Natl Cancer Inst 2009; 101: 37–47.

Kaynak Göster

Bibtex @ { tbtkmedical146666, journal = {Turkish Journal of Medical Sciences}, issn = {1300-0144}, eissn = {1303-6165}, address = {}, publisher = {TÜBİTAK}, year = {2014}, volume = {44}, pages = {586 - 589}, doi = {10.3906/kim-1212-66}, title = {Oxaliplatin and ototoxicity: is it really safe for hearing?}, key = {cite}, author = {Yüce, Salim and Şeker, Mehmet Metin and Koç, Sema and Uysal, İsmail Önder and Kaçan, Turgut and Doğan, Mehtap} }
APA Yüce, S , Şeker, M , Koç, S , Uysal, İ , Kaçan, T , Doğan, M . (2014). Oxaliplatin and ototoxicity: is it really safe for hearing? . Turkish Journal of Medical Sciences , 44 (4) , 586-589 . DOI: 10.3906/kim-1212-66
MLA Yüce, S , Şeker, M , Koç, S , Uysal, İ , Kaçan, T , Doğan, M . "Oxaliplatin and ototoxicity: is it really safe for hearing?" . Turkish Journal of Medical Sciences 44 (2014 ): 586-589 <
Chicago Yüce, S , Şeker, M , Koç, S , Uysal, İ , Kaçan, T , Doğan, M . "Oxaliplatin and ototoxicity: is it really safe for hearing?". Turkish Journal of Medical Sciences 44 (2014 ): 586-589
RIS TY - JOUR T1 - Oxaliplatin and ototoxicity: is it really safe for hearing? AU - Salim Yüce , Mehmet Metin Şeker , Sema Koç , İsmail Önder Uysal , Turgut Kaçan , Mehtap Doğan Y1 - 2014 PY - 2014 N1 - doi: 10.3906/kim-1212-66 DO - 10.3906/kim-1212-66 T2 - Turkish Journal of Medical Sciences JF - Journal JO - JOR SP - 586 EP - 589 VL - 44 IS - 4 SN - 1300-0144-1303-6165 M3 - doi: 10.3906/kim-1212-66 UR - Y2 - 2021 ER -
EndNote %0 Turkish Journal of Medical Sciences Oxaliplatin and ototoxicity: is it really safe for hearing? %A Salim Yüce , Mehmet Metin Şeker , Sema Koç , İsmail Önder Uysal , Turgut Kaçan , Mehtap Doğan %T Oxaliplatin and ototoxicity: is it really safe for hearing? %D 2014 %J Turkish Journal of Medical Sciences %P 1300-0144-1303-6165 %V 44 %N 4 %R doi: 10.3906/kim-1212-66 %U 10.3906/kim-1212-66
ISNAD Yüce, Salim , Şeker, Mehmet Metin , Koç, Sema , Uysal, İsmail Önder , Kaçan, Turgut , Doğan, Mehtap . "Oxaliplatin and ototoxicity: is it really safe for hearing?". Turkish Journal of Medical Sciences 44 / 4 (Mayıs 2014): 586-589 .
AMA Yüce S , Şeker M , Koç S , Uysal İ , Kaçan T , Doğan M . Oxaliplatin and ototoxicity: is it really safe for hearing?. Turkish Journal of Medical Sciences. 2014; 44(4): 586-589.
Vancouver Yüce S , Şeker M , Koç S , Uysal İ , Kaçan T , Doğan M . Oxaliplatin and ototoxicity: is it really safe for hearing?. Turkish Journal of Medical Sciences. 2014; 44(4): 586-589.
IEEE S. Yüce , M. Şeker , S. Koç , İ. Uysal , T. Kaçan ve M. Doğan , "Oxaliplatin and ototoxicity: is it really safe for hearing?", Turkish Journal of Medical Sciences, c. 44, sayı. 4, ss. 586-589, May. 2014, doi:10.3906/kim-1212-66
  • ISSN: 1300-0144
  • Yayın Aralığı: Yılda 6 Sayı
  • Yayıncı: TÜBİTAK

23.5b 22.2b

Sayıdaki Diğer Makaleler

The relationship between lower urinary tract symptoms associated with benign prostatic hyperplasia and erectile dysfunction: the role of autonomic hyperactivity

Mehmet UMUL, Ahmet Barış ALTAY, Fikret BADEMKIRAN, Burak TURNA

The role of hepcidin and its related genes (BMP6, GDF-15, and HJV) in rats exposed to ischemia and reperfusion

Recep DOKUYUCU, Tuncer DEMİR, Önder YUMRUTAŞ, Ayşe Binnur ERBAĞCI, Mustafa ÖRKMEZ

Seasonal variation and risk factors associated with surgical site infection rate in Kano, Nigeria

Emmanuel NWANKWO, Stephen EDINO

The comparison of folate and vitamin B12 levels between depressive and nondepressive postmenopausal women

Özlem ŞENGÜL, Dilek UYGUR, Mustafa GÜLEÇ, Berna DİLBAZ, Esma Meltem ŞİMŞEK, Ümit GÖKTOLGA

Oxaliplatin and ototoxicity: is it really safe for hearing?

Salim YÜCE, Mehmet Metin ŞEKER, Sema KOÇ, İsmail Önder UYSAL, Turgut KAÇAN, Mehtap DOĞAN

Hepatitis C virus genotypes in Adana and Antakya regions of Turkey

Agah Bahadır ÖZTÜRK, Ümit Bilge DOĞAN, Nevin Akçaer ÖZTÜRK

Effects of linoleic acid on generalized convulsive and nonconvulsive epileptic seizures

Fatih EKİCİ, Gönül GÜROL, Nurbay ATEŞ

Migraine prevalence, disability, and sociodemographic properties in the eastern region of Turkey: a population-based door-to-door survey

Gökhan ÖZDEMİR, Recep AYGÜL, Recep DEMİR, Lütfi ÖZEL, Ayfer ERTEKİN, Hızır ULVİ

The effect of lateral internal sphincterotomy on resting anal sphincter pressures

Kemal PEKER, İsmayil YILMAZ, İsmail DEMİRYILMAZ, Abdullah İNAL, Arda IŞIK

Transradial approach in the diagnosis and treatment of coronary artery disease: a 2-center experience

Mustafa YURTDAŞ, Yüksel KAYA, Edip GÖNÜLLÜ